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Abstract
Background: About 130 million people are infected with the hepatitis C virus (HCV) worldwide, but effective
treatment options are not yet available. One of the most promising targets for antiviral therapy is nonstructural
protein 3 (NS3). To identify possible changes in the structure of NS3 associated with virological sustained response
or non-response of patients, a model was constructed for each helicase NS3 protein coding sequence. From this,
the goal was to verify the interaction between helicases variants and their ligands.
Findings: Evidence was found that the NS3 helicase portion of non-responder patients contained substitutions in
its ATP and RNA binding sites. K210E substitution can cause an imbalance in the distribution of loads, leading to a
decrease in the number of ligations between the essential amino acids required for the hydrolysis of ATP. W501R
substitution causes an imbalance in the distribution of loads, leading and forcing the RNA to interact with the
amino acid Thr269, but not preventing binding of ribavirin inhibitor.
Conclusions: Useful information is provided on the genetic profiling of the HCV genotype 3, specifically the
coding region of the NS3 protein, improving our understanding of the viral genome and the regions of its protein
catalytic site.
Background
Hepatitis C virus (HCV) is the main causative agent of
non-A and non-B hepatitis. The clinical manifestations
of infection include acute and chronic forms of hepatitis
C, liver cirrhosis and hepatocellular carcinoma [1]. The
overall prevalence estimated of HCV infection is 2.2%,
which corresponds to 130 million HCV-positive people
in the world [2]. About 3 million people in Brazil are
infected [3].
The HCV genome contains a positive single-stranded
RNA of ~9.6 kb. It encodes a single precursor polypro-
tein containing ~3000 amino acids [4-6], which gives
rise to all viral structural proteins (S) - core (protein C),
envelope 1 (E1) and envelope 2 (E2) - and nonstructural
proteins (NS), located in the following order: NS2, NS3,
NS4A, NS4B, NS5A, and NS5B [7].
The NS3 protein of the hepatitis C virus (HCV) is a
target for development of antiviral agents. It is a hydro-
phobic protein of ~69 kDa, with its serine-protease
function encoded in its N-terminal portion accounting
for one-third of the entire protein [7]. The C-terminal
portion of the structural protein NS3 corresponds to the
helicase domain, having NTPase and RNA helicase
activities [8].
To identify possible changes in the structure of the NS3
protein associated with virologically sustained responder
and non-responder patients, a model was constructed for
each helicase NS3 protein coding sequence.
Methods
Population and samples
The study material consisted of the serum samples of the
16 patients infected with hepatitis C virus genotype 3.
After confirming the positive diagnosis of infection,
defined by positivity for the virus antibody by ELISA and
qualitative PCR for RNA, the patients were given 24 weeks
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of treatment with interferon-alpha and ribavirin, and were
followed-up for up to 6 months after medication. Serum
collections were made at 12 and 24 weeks during treat-
ment, and 7, 14, 21 and 28 days after the treatment had
been completed, then monthly for up to 6 months. Co-
infection with the human immunodeficiency virus (HIV)
and/or with the hepatitis B virus (HBV) was taken as an
exclusion criterion. The project was approved by the
research ethics committee of the São José do Rio Preto
School of Medicine (FAMERP; opinion Nr. 087/2004).
Molecular Modeling
For the modeling of NS3, the restrain-based modeling
approach was used as implemented in the MODELLER
program [9]. A total of 1000 models were generated for
each clone and the final model was selected based on
objective function and stereochemical quality.
The stereochemical evaluation quality of the final
model was assessed by PROCHECK [10], X-PLOR [11],
Verify-3D [12] and WHATCHECK [13] programs.
Molecular Docking Simulations
The Molegro Virtual Docker program (version 2.0) was
used to generate an ensemble of docked conformations
for each variant helicase protein and ATP, RNA and
Ribavirin compounds [14].
Results and discussion
Patients’ characteristics
A total of 16 patients were treated and followed until
6 months after the end of the treatment. Seven patients
(43.7%) presented a virological sustained response
(VSR), of whom 6 were male and 1 was female. Nine
patients (56.3%) presented non-response (NR), 6 being
male and 3 female. Thirteen patients were infected with
HCV genotype 3a and 3 with HCV genotype 3e. The
patients’ average age was 47.7 years (Table 1).
Table 1 Patients’ characteristics
SEX AGE (YEARS) HCV GENOTYPE SUBSTITUTION RESPONSE
RF006 M 39 3a Non-responder
RF007 F 28 3e K210E ATP binding site Non-responder
RF009 M 51 3a Non-responder
RF015 M 50 3a Virological sustained responder
RF018 M 49 3a Virological sustained responder
RF020 M 41 3e W501R RNA binding site Non-responder
RF059 F 54 3a F444S Virological sustained responder
RF060 M 48 3a Non-responder
RF061 M 38 3e Virological sustained responder
RF075 F 46 3a Non-responder
RF080 M 52 3a Virological sustained responder
RF081 M 58 3a Virological sustained responder
RF082 F 57 3a Non-responder
RF096 M 60 3a Virological sustained responder
RF115 M 41 3a Non-responder
RF145 M 51 3a Non-responder
Figure 1 Key residues involved in ATP binding: (A) Template
(PDB1A1V; Kim et al., 1998) [18], (B) patient RF007 showing the
substitution of lysine for glutamic acid at position 210 of NS3.
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Figure 2 Docking simulations between helicase and ATP: (A) patient RF059 and (B) patient RF007.
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Analysis of the substitutions in the sequences NS3
Helicase
Multiple sequence alignment analysis of the helicase
fragment obtained from non-responder patients showed
significant changes in helicase residues, for instance in
the ATP and RNA binding sites. In patient RF007, a
substitution of Lys210 for Glu210 occurred at the ATP
binding site (Table 1). In the RNA binding site, patient
RF020 had a Trp501 to Arg501 substitution (Table 1).
No substitutions were found in the terminal region of
the loop corresponding to a hydrophobic region
(Phe531, Phe536 and Trp532). The arginine residue at
position 393, important in the design of specific HCV
NS3 inhibitors, was also assessed, but no changes were
detected (Figure S1 of additional file 1).
PROTEUS showed variation in the number of a-helix,
beta-sheet and coil structures in all resistant patients
(diagram I of additional file 1). The PROTPARAM analy-
sis showed the substitutions in the protein’s amino acids
composition which leads to and compromises the struc-
ture as a whole in resistant patients (diagram II of addi-
tional file 1). However, since these are theoretical models,
experimental techniques will be used to confirm the
structural differences observed in the helicase portion,
and to investigate whether there is a reduction of its affi-
nity for the ligands. The elements of the tertiary structure
showing that the substitutions subtly alter the quantita-
tion of the secondary structure in Non-Responder
patients due an increase in the random structure regions
are shown in Figures S2A-S2C of additional file 1.
Analysis of the helicase ATP-binding site
Mutations in motifs I to VI located in the helicase
domains 1 and 2 can impact on the ability of the protein
to unwind genetic material and hydrolyze ATP, showing
that these two activities are co-operative. Here, we have
highlighted the K210E substitution (Table 1), which
leads to a change of a positive to a negative charge in
the altered residue (Figures 1A and 1B), a different
charge distribution and interactions between amino
acids that might interfere with the hydrolysis of ATP.
To verify that the consequences the K210E substitu-
tion led to interaction with ATP, docking simulations
were performed between helicase variant and the com-
post. The exchange of charges due to the substitution
produced an imbalance in the distribution of loads, lead-
ing to a decrease in the number of ligations between the
essential amino acids for the exercise of hydrolysis of
ATP (Figures 2A-2B). ATP and a required metal ion
cofactor (i.e. Mg2+) normally bind to a helicase in the
cleft that separates two adjacent RecA-like domains.
The most critical residues for ATP binding arise from
the Walker A and B motifs. The Walker A motif of
HCV helicase forms a phosphate binding loop (P-loop)
with the conserved Lys210, thereby probably contacting
the g phosphate of ATP [15]. With this disturbance,
substitution of Lys210 caused a mild disruption of the
molecule accompanied by a change in its orientation.
Kim et al. [16] through site-directed mutations
showed that the K210E mutant lost its RNA helicase
activity and had very little NTPase activity compared to
the wild-type protein. Similar results were observed by
Chang et al. [17], in which the ATPase activity was sig-
nificantly reduced in mutant NS3 proteins (K210E).
They also observed that the wild type NS3 protein com-
pletely unwound the RNA substrate in the presence of
ATP, but the mutation (K210E) completely abrogated
the activity.
Analysis of the helicase RNA-binding site
The substitution (W501R; see Table 1) of a non-polar
(neutral) amino acid for a polar (positive) residue
(Figures 3A and 3B) leads to an increase of positivity
in this region and thus alters the interaction of the
protein with its environment. Docking simulations
between helicase variant and the RNA substract
Figure 3 (A) Key residues in contact with an oligonucleotide
bound to the helicase template (PDB 1A1V; Kim et al., 1998)
[18]; (B) Substitution of tryptophan for arginine at position 501
of NS3, present in patient RF020.
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Figure 4 Docking simulations between helicase and RNA substract: (A) patient RF059 and (B) patient RF020.
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Figure 5 Docking simulations between helicase and Ribavirin substract: (A) patient RF059 and (B) patient RF020.
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showed that the substitution of tryptophan by arginine
at position 501 causes an imbalance in the distribution
of loads leading, and forces the RNA to interact with
the amino acid, Thr269. In this case, we observed an
increase in the positive charges near to R501 (Figures
4A and 4B).
Based on the observation that the oligonucleotide
appears to be locked in the binding cleft because a resi-
due in domain 3, Trp501, is stacked against the 3′-term-
inal base, Kim et al. [18], proposed that ATP binding,
and the subsequent closure of the cleft between
domains 1 and 2, will lead to a ratcheting of Trp501
past 1 or 2 nucleotides. Consequently, the protein
would move towards the 5′-end of the bound nucleic
acid. After ATP is hydrolyzed and Trp501 is once more
locked into a place acting as a bookend, the cleft opens
and RNA slides through to the other side of the protein.
Consequently the replacement of W501 prevents the
correct movement of the protein in the “ratcheting
inchworm” model first proposed for HCV helicase by
Kim et al. [18].
Since interferon-alpha did not act as a protease inhibi-
tor, we also performed docking simulations between the
variant protein W501R and the compound Ribavirin to
find a correlation between the substitutions found in
Helicase and the response of patients to treatment. This
inhibitor connects to altered Helicase the same way that
as in Helicase wild type, independent of the substitution
of tryptophan by arginine at position 501, and thereby
maintaining its function (Figures 5A-5B). From this, we
infer that the mutation does not prevent the binding of
inhibitor, but indicates that this is not the reason for the
lack of response to treatment.
Conclusions
Natural occurrence of amino acids substitution in non-
responder HCV patients has been explored for impor-
tant sites in relation to the perfect excise of helicase
function. Correlations of the variants L210E and W501R
with patients’ responses to the treatment may not be
valid at this time because other forms of viruses that
have the helicase in their wild types are predominant in
the patient, thus ensuring viral replication. It is impor-
tant to find these variants so that future enzymatic stu-
dies can be carried out on them. Individual analysis of
treatment with future inhibitors can be important to
treatment response.
Additional material
Additional file 1: Methods, Figure S1 and Figure S2Methods, Figure
S1 and S2
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